Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion
- Registration Number
- NCT00422201
- Lead Sponsor
- HRA Pharma
- Brief Summary
This study will evaluate whether the drug mifepristone can improve the symptoms of Cushing's syndrome in people with ectopic adrenal corticotrophin hormone (ACTH) secretion. Cushing's syndrome occurs when the adrenal glands produce too much cortisol, a hormone that helps to regulate the body's use of salt and food. Excessive cortisol is usually the result of too much ACTH, the hormone that causes the adrenal glands to make cortisol. The extra ACTH is made either by a tumor in the pituitary gland (called Cushing's disease) or by a tumor somewhere else (called ectopic ACTH secretion). Mifepristone blocks the action of cortisol in the body. The drug has been used safely to treat a few people with Cushing's syndrome and patients with certain kinds of cancer, gynecological diseases and psychiatric disorders.
People between 18 and 85 years of age with Cushing's syndrome caused by EXCESS ACTH secretion may be eligible for this study. Candidates are admitted to the hospital for evaluation to confirm Cushing's syndrome and to determine its cause. The evaluation includes blood and urine tests, imaging tests, dexamethasone and corticotropin-releasing hormone tests and inferior petrosal sinus sampling. Patients determined to have Cushing's syndrome due to ECTOPIC ACTH secretion undergo imaging studies (CT, MRI and a nuclear medicine scan) and begin mifepristone therapy.
Participants remain in the hospital for the following tests and procedures:
* Physical examination, electrocardiogram (EKG) and blood and urine tests
* Completion of medical questionnaires
* DEXA scan to determine bone mineral density and body composition
* Glucose tolerance test
* Urine pregnancy test and ultrasound to measure uterine lining thickness (for women)
Patients take mifepristone by mouth 3 times a day. The dose is increased every week or so until symptoms improve or the highest dosage allowed is reached. Patients may remain in the hospital for all or part of the dose-finding part of the study. During this period (usually 2 to 4 weeks), blood pressure, glucose tolerance and blood chemistries are measured and EKG and urinalysis done every 5 to 14 days. When the mifepristone dose is stable patients remain on that dose for at least 2 weeks and are then re-evaluated. Patients then return to the hospital for evaluations every 3 months. Those who do well on the drug may continue to take it for up to 12 months.
- Detailed Description
Between 10% and 20% of patients with hypercortisolism (Cushing's Syndrome) have tumoral ectopic production of adrenocorticotropin hormone (ACTH) that causes cortisol excess. If an ectopic tumor cannot be found or if surgery cannot be done, the treatment options include medicines that reduce cortisol production and bilateral adrenalectomy. The available medications that reduce cortisol production have important adverse effects and are not effective in some patients and adrenalectomy leads to lifelong requirements for medical hormone replacement. Thus, additional treatment options would be welcome. This study evaluates a potential new medication for the treatment of these patients; mifepristone blocks the effects of cortisol rather than decreasing its production. The purpose of this study is to see whether this agent can improve diabetes or other symptoms of Cushing's syndrome in subjects with ectopic ACTH secretion. Another purpose is to evaluate adverse effects with this drug. Patients with presumed ectopic ACTH secretion and diabetes will take mifepristone 600 mg daily by mouth, and the effect on diabetes and other symptoms of Cushing's syndrome will be measured. Subjects will return to the hospital at 2, 3, 6, 9, and 12 months after starting mifepristione for evaluation of diabetes and other symptoms. The agent will be available for up to 12 months for patients in whom it is effective.
Patients take mifepristone by mouth 3 times a day. Each dose will contain 200 mg. Patients may remain in the hospital for all or part of the initial safety studies, every two weeks for eight weeks. During this period blood pressure, glucose tolerance and blood chemistries are measured and EKG and urinalysis done every two weeks. The mifepristone dose can be decreased or stopped if there are adverse effects. When the mifepristone dose is stable for eight weeks, patients will be re-evaluated. Patients then return to the hospital for evaluations one month later and then every 3 months. Those who do well on the drug may continue to take it for up to 12 months.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 18
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Prospective, open-label, study of mifepristone Mifepristone Eligible subjects will start study treatment at the dose of 600 mg/day (given as one 200 mg tablet tid, per os). Total duration of treatment will not exceed 12 months. At the end of 12-month treatment, investigators may petition to extend treatment on a case-by-case basis.
- Primary Outcome Measures
Name Time Method Glycemic Disorders Improved or Normalized 8 weeks at steady dose Criteria for improvement or normalization of glycemic disorders:
A. For diabetic patients (known or diagnosed at pre-inclusion visit)
* Decrease in HbA1c \> 0.3% B. For patients with IGT
* Normalization of OGTT (2-hour glucose plasma level after 75 g OGTT \< 7.8 mmol/L (140 mg/dL) D. For patients with IFG
If impaired fasting glucose is also associated with impaired glucose tolerance during OGTT at pre-inclusion:
- Normalization of OGTT (2-hour glucose plasma level after 75 g OGTT \< 7.8 mmol/L (140 mg/dL)
If impaired fasting glycemia is associated with normal OGTT at pre-inclusion (except at T0):
- Normalization of fasting plasma glucose (fasting plasma glucose \< 5.5 mmol/L (100 mg/dL)
- Secondary Outcome Measures
Name Time Method Features of Cushing's Syndrome 8 weeks at steady dose Criteria for secondary glycemic disorder improvement of clinical symptoms attributable to the Cushing's syndrome A. For diabetic patients
* Improvement of the following parameters: glycemic profile, fasting blood glucose, fructosamine, 2-hour OGTT (for diabetics diagnosed at screening)
* Number of anti-diabetics treatment or dose of anti-diabetics treatment for diabetic patients already on diabetes treatment at inclusion
* Doses of insulin for insulin-treated patients B. For patients with IGT
* HbA1c
* Fructosamine C. For patients with IFG
* HbA1c
* Fructosamine D. For all patients
* Fasting plasma insulin
* Area Under the Curve of OGTT results when OGTT performed
* HOMA index
Trial Locations
- Locations (15)
National Institutes of Health Clinical Center, 9000 Rockville Pike
🇺🇸Bethesda, Maryland, United States
CHU de Bordeaux Hopital Haut Leveque
🇫🇷Bordeaux, France
C.H.U Albert Michallon
🇫🇷Grenoble, France
C.H.U. de Bicetre
🇫🇷Le Kremlin-Bicêtre, France
CHRU de Lille
🇫🇷Lille, France
Hopital de la Timone
🇫🇷Marseille, France
AP-HP, Hopital Cochin Pavillon CORNIL
🇫🇷Paris, France
CHU de Toulouse
🇫🇷Toulouse, France
University of Wuerzburg
🇩🇪Wuerzbug, Germany
Universita Degli Studi
🇮🇹Napoli, Italy
Scroll for more (5 remaining)National Institutes of Health Clinical Center, 9000 Rockville Pike🇺🇸Bethesda, Maryland, United States